For the quarter ended June 2026, Guardant Health (GH) reported revenue of $334.98 million, up 44.3% over the same period last year. EPS came in at -$0.42, compared to -$0.44 in the year-ago quarter.

The reported revenue represents a surprise of +6.01% over the Zacks Consensus Estimate of $316 million. With the consensus EPS estimate being -$0.40, the EPS surprise was -5%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Shield screening tests: 66,000 versus the three-analyst average estimate of 52,118.
  • Total tests performed (oncology tests): 104,000 versus the three-analyst average estimate of 89,203.
  • Revenue- Oncology: $219.11 million compared to the $211.43 million average estimate based on four analysts. The reported number represents a change of +38.1% year over year.
  • Revenue- Licensing and other: $2.06 million versus the four-analyst average estimate of $2.1 million. The reported number represents a year-over-year change of -19.8%.
  • Revenue- Screening: $52.87 million versus the four-analyst average estimate of $44.83 million. The reported number represents a year-over-year change of +256.9%.
  • Revenue- Biopharma and data: $60.95 million compared to the $57.89 million average estimate based on four analysts. The reported number represents a change of +8.8% year over year.

View all Key Company Metrics for Guardant Health here>>>

Shares of Guardant Health have returned -15.6% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Guardant Health, Inc. (GH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research